Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
| ▸ | GNMT | Q14749 | 2/20 | 0.52 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.52 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.51 |
| ▸ | NNMT | P40261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22343548 | 1.00 | ADORA1 (0.52) | ADORA1GNMTTRPM2METTL3NNMT | |
| SCHEMBL22323629 | 0.94 | GNMT (0.56) | ADORA1GNMTTRPM2 | |
| SCHEMBL22343636 | 0.88 | BCHE (0.45) | GNMTNNMT | |
| SCHEMBL22343666 | 0.88 | GNMT (0.56) | ADORA1GNMTTRPM2METTL3 | |
| SCHEMBL22343533 | 0.86 | GNMT (0.57) | ADORA1GNMTTRPM2METTL3 | |
| SCHEMBL29702996 | 0.84 | ADORA1 (0.54) | ADORA1GNMTTRPM2METTL3 | |
| SCHEMBL22343675 | 0.83 | ADH1A (0.53) | ADORA1GNMTTRPM2METTL3 | |
| SCHEMBL22343635 | 0.82 | BCHE (0.46) | GNMT | |
| SCHEMBL22343764 | 0.81 | ADORA1 (0.54) | ADORA1GNMTTRPM2 | |
| SCHEMBL22343634 | 0.81 | AHCY (0.45) | GNMTNNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235088-A1 | INHIBITORS OF ADENYLATE-FORMING ENZYME MENE | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235088-A1 | INHIBITORS OF ADENYLATE-FORMING ENZYME MENE | ADSL, MEN1, AMD1 | ADORA1 309/4885GNMT 526/4885TRPM2 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.